INCY

Incyte Corporation · Healthcare · Biotechnology
$96.74
-0.76 (-0.78%)
Mkt Cap: 19.33B
Key Metrics
MetricValue
P/E RatioN/A
EV/EBITDAN/A
ROEN/A
Gross MarginN/A
Revenue GrowthN/A
FCF Yield7.0%
Dividend YieldN/A
Market Cap19.33B
Volume2.32M
Recent News
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie
gurufocus.com · 2026-05-30
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
reuters.com · 2026-05-30
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
businesswire.com · 2026-05-30
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
zacks.com · 2026-05-28
Here's Why Incyte (INCY) is a Strong Momentum Stock
zacks.com · 2026-05-26
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
gurufocus.com · 2026-05-26

Unlock the Full Deep Scan

9 AI agents analyze INCY across earnings, insider flow, macro conditions, corporate strategy, market microstructure, and price action.

Sign Up Free →